These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

795 related articles for article (PubMed ID: 28056738)

  • 21. Molecular mechanism of action of microtubule-stabilizing anticancer agents.
    Prota AE; Bargsten K; Zurwerra D; Field JJ; Díaz JF; Altmann KH; Steinmetz MO
    Science; 2013 Feb; 339(6119):587-90. PubMed ID: 23287720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tubulin inhibitors as novel anticancer agents: an overview on patents (2013-2018).
    Haider K; Rahaman S; Yar MS; Kamal A
    Expert Opin Ther Pat; 2019 Aug; 29(8):623-641. PubMed ID: 31353978
    [No Abstract]   [Full Text] [Related]  

  • 23. Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function.
    Field JJ; Kanakkanthara A; Miller JH
    Bioorg Med Chem; 2014 Sep; 22(18):5050-9. PubMed ID: 24650703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estradiol dimer inhibits tubulin polymerization and microtubule dynamics.
    Jurášek M; Černohorská M; Řehulka J; Spiwok V; Sulimenko T; Dráberová E; Darmostuk M; Gurská S; Frydrych I; Buriánová R; Ruml T; Hajdúch M; Bartůněk P; Dráber P; Džubák P; Drašar PB; Sedlák D
    J Steroid Biochem Mol Biol; 2018 Oct; 183():68-79. PubMed ID: 29803726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death.
    Dumontet C; Sikic BI
    J Clin Oncol; 1999 Mar; 17(3):1061-70. PubMed ID: 10071301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An overview on anti-tubulin agents for the treatment of lymphoma patients.
    Barreca M; Stathis A; Barraja P; Bertoni F
    Pharmacol Ther; 2020 Jul; 211():107552. PubMed ID: 32305312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microtubule associated proteins as targets for anticancer drug development.
    Khwaja S; Kumar K; Das R; Negi AS
    Bioorg Chem; 2021 Nov; 116():105320. PubMed ID: 34492559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanism of action of antitumor drugs that interact with microtubules and tubulin.
    Jordan MA
    Curr Med Chem Anticancer Agents; 2002 Jan; 2(1):1-17. PubMed ID: 12678749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of Novel Bis(indolyl)-hydrazide-Hydrazone Derivatives as Potent Microtubule-Targeting Cytotoxic Agents against A549 Lung Cancer Cells.
    Das Mukherjee D; Kumar NM; Tantak MP; Das A; Ganguli A; Datta S; Kumar D; Chakrabarti G
    Biochemistry; 2016 May; 55(21):3020-35. PubMed ID: 27110637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.
    Smiyun G; Azarenko O; Miller H; Rifkind A; LaPointe NE; Wilson L; Jordan MA
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):151-164. PubMed ID: 28567478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity.
    Buey RM; Barasoain I; Jackson E; Meyer A; Giannakakou P; Paterson I; Mooberry S; Andreu JM; Díaz JF
    Chem Biol; 2005 Dec; 12(12):1269-79. PubMed ID: 16356844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, and biological evaluation of novel combretastatin A-4 thio derivatives as microtubule targeting agents.
    Stefański T; Mikstacka R; Kurczab R; Dutkiewicz Z; Kucińska M; Murias M; Zielińska-Przyjemska M; Cichocki M; Teubert A; Kaczmarek M; Hogendorf A; Sobiak S
    Eur J Med Chem; 2018 Jan; 144():797-816. PubMed ID: 29291446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new perspective on old drugs: non-mitotic actions of tubulin-binding drugs play a major role in cancer treatment.
    Fürst R; Vollmar AM
    Pharmazie; 2013 Jul; 68(7):478-83. PubMed ID: 23923626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cytoskeleton as a therapeutic target in childhood acute leukemia: obstacles and opportunities.
    Liaw TY; Chang MH; Kavallaris M
    Curr Drug Targets; 2007 Jun; 8(6):739-49. PubMed ID: 17584029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toward Discovery of Novel Microtubule Targeting Agents: A SNAP-tag-Based High-Content Screening Assay for the Analysis of Microtubule Dynamics and Cell Cycle Progression.
    Berges N; Arens K; Kreusch V; Fischer R; Di Fiore S
    SLAS Discov; 2017 Apr; 22(4):387-398. PubMed ID: 28328318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural comparison of the interaction of tubulin with various ligands affecting microtubule dynamics.
    Stec-Martyna E; Ponassi M; Miele M; Parodi S; Felli L; Rosano C
    Curr Cancer Drug Targets; 2012 Jul; 12(6):658-66. PubMed ID: 22385515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epothilones: From discovery to clinical trials.
    Forli S
    Curr Top Med Chem; 2014; 14(20):2312-21. PubMed ID: 25434353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microtubules: a dynamic target in cancer therapy.
    Pasquier E; Kavallaris M
    IUBMB Life; 2008 Mar; 60(3):165-70. PubMed ID: 18380008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New microtubule/tubulin-targeted anticancer drugs and novel chemotherapeutic strategies.
    Wilson L; Jordan MA
    J Chemother; 2004 Nov; 16 Suppl 4():83-5. PubMed ID: 15688618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dietary flavonoid fisetin binds to β-tubulin and disrupts microtubule dynamics in prostate cancer cells.
    Mukhtar E; Adhami VM; Sechi M; Mukhtar H
    Cancer Lett; 2015 Oct; 367(2):173-83. PubMed ID: 26235140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.